ILEX Begins Phase I/II Trial of Campath in CD52-Positive NHL

SAN ANTONIO—ILEX Oncology, Inc. has launched the first ILEX-sponsored study of Campath (alemtuzumab) in patients with CD52-antigen-positive relapsing or refractory non-Hodgkin’s lymphoma (NHL). Campath is a humanized monoclonal antibody directed against the CD52 antigen.

The trial, designed to determine the appropriate dose in a weekly schedule, marks the first time ILEX is studying Campath in a disease in which the CD52 antigen appears to be highly expressed, the company said in a news release. Campath is FDA approved for patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and have failed fludarabine (Fludara) treatment.